G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
Piyanuch Kongtim,Piyanuch Kongtim,Uday R. Popat,Antonio M. Jimenez,Sameh Gaballa,Riad El Fakih,Gabriela Rondon,Julianne Chen,Carlos E. Bueso-Ramos,Gautam Borthakur,Naveen Pemmaraju,Guillermo Garcia-Manero,Hagop M. Kantarjian,Amin M. Alousi,Chitra Hosing,Paolo Anderlini,Issa F. Khouri,Partow Kebriaei,Borje S. Andersson,Betul Oran,Katy Rezvani,David Marin,Elizabeth J. Shpall,Richard E. Champlin,Stefan O. Ciurea +24 more
TL;DR: The data support the use of hypomethylating agents before allo-SCT for patients with CMML to achieve morphologic remission and improve PFS of these patients.
Journal ArticleDOI
Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
Ohad Benjamini,Theresa Liu Dumlao,Hagop M. Kantarjian,Susan O'Brien,Guillermo Garcia-Manero,Stefan Faderl,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Rebecca Garris,Deborah A. Thomas,Partow Kebriaei,Richard E. Champlin,Elias Jabbour,Jan A. Burger,Jorge E. Cortes,Farhad Ravandi +15 more
TL;DR: The combination of HyperCVAD regimen with dasatinib is effective in patients with relapsed Ph‐positive ALL and CML‐LB.
Journal ArticleDOI
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
TL;DR: An overview of current treatment modalities in Ph-positive ALL, the introduction of the tyrosine kinase inhibitors such as STI571, and the rationale for new therapies will be discussed.
Journal ArticleDOI
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Deborah A. Thomas,Hagop M. Kantarjian,Wendy Stock,Leonard T. Heffner,Stefan Faderl,Guillermo Garcia-Manero,Alessandra Ferrajoli,William G. Wierda,Sherry Pierce,Biao Lu,Steven R. Deitcher,Susan O'Brien +11 more
TL;DR: Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity.
Journal ArticleDOI
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C. Issa,Hagop M. Kantarjian,C. Cameron Yin,Wei Qiao,Farhad Ravandi,Deborah A. Thomas,Nicholas J. Short,Koji Sasaki,Guillermo Garcia-Manero,Tapan M. Kadia,Jorge E. Cortes,Naval Daver,Gautam Borthakur,Nitin Jain,Marina Konopleva,Issa F. Khouri,Partow Kebriaei,Richard E. Champlin,Sherry Pierce,Susan O'Brien,Elias Jabbour +20 more
TL;DR: The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia.